Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

NCT02422641 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Leptomeningeal Disease

Interventions

DRUG: High-dose Methotrexate (8 gm/m2; HD-MTX)

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]